Marc Goeders, PA
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.3% of the total across 38 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 23.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $529 and has fallen 67.9% since, to $170 in 2025.
Across 38 payments — averaging $26.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$228
- Myriad Genetic Laboratories, Inc.$156
- Stryker$91
- Urogen Pharma, Inc.$84
- AbbVie$44
- Johnson & Johnson$44
- plus $343 from 16 others
What the payments were for
- Food & beverage$96497%
- Education$273%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 6 | $228 |
| Myriad Genetic Laboratories, Inc. | 4 | $156 |
| Stryker | 2 | $91 |
| Urogen Pharma, Inc. | 4 | $84 |
| AbbVie | 2 | $44 |
| Johnson & Johnson | 1 | $44 |
| E.r. Squibb & Sons, L.L.C. | 2 | $33 |
| Astellas Pharma US Inc | 2 | $30 |
| Coloplast | 2 | $29 |
| Accord Healthcare, Inc. | 1 | $26 |
| Olympus America Inc. | 1 | $26 |
| Calyxo, Inc. | 1 | $25 |
| Laborie Medical Technologies Corp. | 1 | $20 |
| Boston Scientific | 1 | $20 |
| Smith+Nephew | 1 | $20 |
| Pfizer | 1 | $19 |
| Endo USA, Inc. | 1 | $17 |
| Vertex | 1 | $17 |
| AstraZeneca | 1 | $17 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $16 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
| Progenics Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$132
How this compares
$991 in reported general payments places this provider in the 65th percentile of 49 surgical providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 137 | $72,654 |
| MyrbetriqMirabegron | 82 | $41,993 |
| Tamsulosin Hcl | 444 | $4,224 |
| Estradiol | 50 | $4,108 |
| Solifenacin Succinate | 90 | $3,741 |
| Methenamine Hippurate | 57 | $3,203 |
| Trospium Chloride | 78 | $2,915 |
| Oxybutynin Chloride ErOxybutynin Chloride | 143 | $2,566 |
| Potassium Citrate ErPotassium Citrate | 24 | $1,533 |
| Testosterone Cypionate | 11 | $720 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 31 | $468 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 78 | $375 |
| Finasteride | 107 | $350 |
| Cephalexin | 49 | $306 |
| Acetic Acid | 20 | $204 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $15 | $72,654137 claims |
| Astellas Pharma US IncMyrbetriq | $30 | $41,99382 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 49 surgical providers in Iowa.
Other surgical in Clive
- Jordan ReinerClive$5K
- Betsy BoltonClive$858
- Hannah McConnahaClive$622
- Dudley PhippsDes Moines$173K
- Chad QuistDes Moines$40K
- Gary AldrichCedar Rapids$10K
- Joel RandDes Moines$4K
- Lauren CooperIowa City$3K
- Ann HallCouncil Bluffs$3K
- Amanda McDonaghCedar Rapids$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.